Evidence map›Paper›PMID 35197632›Full record

ArticleNature2022

A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.

Edward Seung, Zhen Xing, Lan Wu, Ercole Rao, Virna Cortez-Retamozo, Beatriz Ospina, Liqing Chen, Christian Beil, Zhili Song, Bailin Zhang and 18 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 98 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 1 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. CD4Cancer biology & medicine · 2026
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 4 countries.

Edward Seung *Sanofi R&D, North America, Cambridge, MA, USA.
Zhen Xing *Sanofi R&D, North America, Cambridge, MA, USA.
Lan WuSanofi R&D, North America, Cambridge, MA, USA.
Ercole RaoSanofi R&D, Frankfurt, Frankfurt am Main, Germany.
Virna Cortez-RetamozoSanofi R&D, North America, Cambridge, MA, USA.
Beatriz OspinaSanofi R&D, North America, Cambridge, MA, USA.
Liqing ChenSanofi R&D, North America, Cambridge, MA, USA.
Christian BeilSanofi R&D, Frankfurt, Frankfurt am Main, Germany.
Zhili SongSanofi R&D, North America, Cambridge, MA, USA.
Bailin ZhangSanofi R&D, North America, Cambridge, MA, USA.
Mikhail LevitSanofi R&D, North America, Cambridge, MA, USA.
Gejing DengSanofi R&D, North America, Cambridge, MA, USA.
Andrew HebertSanofi R&D, North America, Cambridge, MA, USA.
Patrick KirbySanofi R&D, North America, Cambridge, MA, USA.
Aiqun LiSanofi R&D, North America, Cambridge, MA, USA.
Emma-Jane PoultonSanofi R&D, North America, Cambridge, MA, USA.
Rita VicenteSanofi R&D, Montpellier, Montpellier, France.
Audrey GarrigouSanofi R&D, Montpellier, Montpellier, France.
Peter PiepenhagenSanofi R&D, North America, Cambridge, MA, USA.
Greg UlinskiSanofi R&D, North America, Cambridge, MA, USA.
Michele Sanicola-NadelSanofi R&D, North America, Cambridge, MA, USA.
Dinesh S BangariSanofi R&D, North America, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9909-1146
Huawei QiuSanofi R&D, North America, Cambridge, MA, USA.
Lily PaoSanofi R&D, North America, Cambridge, MA, USA. Lily.Pao@sanofi.com.ORCID http://orcid.org/0000-0002-7626-2782
Dmitri WiederschainSanofi R&D, North America, Cambridge, MA, USA.
Ronnie WeiSanofi R&D, North America, Cambridge, MA, USA.
Zhi-Yong YangSanofi R&D, North America, Cambridge, MA, USA. Zhi-yong.Yang@modextx.com.ORCID http://orcid.org/0000-0002-9938-5929
Gary J NabelSanofi R&D, North America, Cambridge, MA, USA. Gary.Nabel@modextx.com.ORCID http://orcid.org/0000-0003-0619-4419
Sanofi (United States) · USSanofi (France) · FRSanofi (Germany) · DEAVEO Oncology (United States) · USIDEXX Laboratories (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective antitumour immunity depends on the orchestration of potent T cell responses against malignancies

Indexed as

Breast NeoplasmsAnimalsCD28 AntigensCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesErb-b2 Receptor Tyrosine KinasesFemaleHumansMiceCD28 AntigensERBB2 protein, humanErbb2 protein, mouseErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID35197632
OpenAlexW4212784707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.